1. Home
  2. CBL vs DBVT Comparison

CBL vs DBVT Comparison

Compare CBL & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

N/A

Current Price

$36.94

Market Cap

1.2B

Sector

Real Estate

ML Signal

N/A

DBVT

DBV Technologies S.A.

N/A

Current Price

$19.87

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBL
DBVT
Founded
1978
2002
Country
United States
France
Employees
N/A
90
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
CBL
DBVT
Price
$36.94
$19.87
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$45.00
$31.75
AVG Volume (30 Days)
116.2K
235.3K
Earning Date
05-04-2026
04-29-2026
Dividend Yield
4.87%
N/A
EPS Growth
132.09
N/A
EPS
4.34
N/A
Revenue
$578,373,000.00
$4,151,000.00
Revenue This Year
N/A
$65.50
Revenue Next Year
N/A
$47.02
P/E Ratio
$8.50
N/A
Revenue Growth
12.18
N/A
52 Week Low
$21.10
$3.91
52 Week High
$38.97
$26.19

Technical Indicators

Market Signals
Indicator
CBL
DBVT
Relative Strength Index (RSI) 47.27 43.78
Support Level $36.49 $8.76
Resistance Level $37.18 $24.47
Average True Range (ATR) 0.99 1.33
MACD -0.12 -0.23
Stochastic Oscillator 27.68 20.04

Price Performance

Historical Comparison
CBL
DBVT

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: